Invesco Ltd. Crinetics Pharmaceuticals, Inc. Transaction History

Invesco Ltd.

$453 Billion
Q1 2024

A detailed history of Invesco Ltd. transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Invesco Ltd. holds 176,943 shares of CRNX stock, worth $7.93 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

176,943

Previous 171,837 2.97%

Holding current value

$7.93 Million

Previous $6.11 Million 35.48%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$34.76 - $46.81 $177,484 - $239,011	5,106 Added 2.97%	176,943 $8.28 Million
Q4 2023 Feb 12, 2024	SELL	$25.62 - $37.07 $141,832 - $205,219	-5,536 Reduced 3.12%	171,837 $6.11 Million
Q3 2023 Nov 13, 2023	BUY	$15.97 - $30.59 $2.23 Million - $4.28 Million	139,796 Added 372.03%	177,373 $5.28 Million
Q2 2023 Aug 11, 2023	SELL	$15.73 - $23.6 $13,103 - $19,658	-833 Reduced 2.17%	37,577 $677,000
Q1 2023 May 12, 2023	BUY	$15.31 - $21.1 $308,174 - $424,721	20,129 Added 110.11%	38,410 $616,000

Q4 2022 Feb 13, 2023	SELL	$15.49 - $19.05 $5,669 - $6,972	-366 Reduced 1.96%	18,281 $334,000
Q3 2022 Nov 14, 2022	SELL	$18.11 - $22.37 $41,145 - $50,824	-2,272 Reduced 10.86%	18,647 $366,000
Q2 2022 Aug 15, 2022	BUY	$16.49 - $27.64 $25,988 - $43,560	1,576 Added 8.15%	20,919 $390,000
Q1 2022 May 16, 2022	SELL	$17.15 - $28.31 $2.93 Million - $4.84 Million	-170,892 Reduced 89.83%	19,343 $425,000
Q4 2021 Feb 14, 2022	BUY	$19.35 - $28.41 $3.36 Million - $4.94 Million	173,734 Added 1052.87%	190,235 $5.4 Million
Q3 2021 Nov 15, 2021	BUY	$16.88 - $25.23 $47,247 - $70,618	2,799 Added 20.43%	16,501 $347,000
Q2 2021 Aug 17, 2021	BUY	$15.9 - $21.15 $217,861 - $289,797	13,702 New	13,702 $258,000

Others Institutions Holding CRNX

# of Institutions

220

Shares Held

75.8M

Call Options Held

631K

Put Options Held

749K

View Full List

About Crinetics Pharmaceuticals, Inc.

Ticker CRNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,752,800
Market Cap $2.41B
Description
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...

More about CRNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.

Account